慢性肾脏病高磷血症与心血管疾病的相关性及防治进展
摘要
<正>磷为人体内最丰富的元素之一,是维持骨骼和牙齿的必要物质,参与了能量代谢、信号传导、蛋白质合成等一系列重要的生命过程。体内磷大多数与氧复合成磷酸盐,磷酸盐的内环境稳态是通过肠道的吸收、肾脏的重吸收,以及细胞外和骨贮存池之间磷酸盐的转换而完成的。慢性肾脏病(CKD)患者由于肾功能紊乱及甲状旁腺激素分泌异常等常导致高磷血
引文
[1]TONELLI M,SACKS F,PFEFFER M,et al.Relation between serum phosphate level and cardiovascular event rate in people with coronary disease[J].Circulation,2005,112(17):2627-2633.
[2]AGAR BU,AKONUR A,LO YC,et al.Kinetic model of phosphorus mobilization during and after short and conventional hemodialysis[J].Clin J Am Soc Nephrol,2011,6(12):2854-2860.
[3]罗智环,陈俊,闵新文.血管平滑肌细胞在血管中膜钙化中的作用研究进展[J].中国医药报导,2016,13(11):31-34.
[4]石凯峰,张宁,刘世巍,等.高磷血症致慢性肾脏病血管钙化的研究及治疗进展[J].世界中医药,2017,12(2):465-469.
[5]JOVANOVICH A,CHONCHOL M.Chronic kidney disease:reductions in FGF-23levels associated with improved outcomes[J].Nat Rev Nephrol,2015,11(10):572-573.
[6]HU MC,SHI M,ZHANG J,et al.Klotho deficiency causes vascular calcification in chronic kidney disease[J].J Am Soc Nephrol,2011,22(1):124-136.
[7]HUM JM,O′BRYAN LM,TATIPARTHI AK,et al.Chronic hyperphosphatemia and vascular calcification are reduced by stable delivery of soluble klotho[J].J Am Soc Nephrol,2017,28(4):1162-1174.
[8]CHENG L,ZHANG L,YANG J,et al.Activation of peroxisome proliferator-activated receptor gamma inhibits vascular calcification by upregulating Klotho[J].Exp Ther Med,2017,13(2):467-474.
[9]DONATE-CORREA J,MARTN-NUEZ E,MORA-FERNNDEZC,et al.Klotho in cardiovascular disease:Current and future perspectives[J].World J Biol Chem,2015,6(4):352-357.
[10]WANG N,WANG X,SUN B,et al.Role of TGF-β1in production of fibronectin in vascular smooth muscle cells cultured under highphosphate conditions[J].J Nephrol,2013,26(1):213-218.
[11]SEZER S,TUTAL E,BAL Z,et al.Differential influence of vitamin D analogs on left ventricular mass index in maintenance hemodialysis patients[J].Int J Artif Organs,2014,37(2):118-125.
[12]GRABNER A,AMARAL AP,SCHRAM K,et al.Activation of Cardiac Fibroblast Growth Factor Receptor 4Causes Left Ventricular Hypertrophy[J].Cell Metab,2015,22(6):1020-1032.
[13]LEIFHEIT-NESTLER M,GROβE SIEMER R,FLASBART K,et al.Induction of cardiac FGF23/FGFR4expression is associated with left ventricular hypertrophy in patients with chronic kidney disease[J].Nephrol Dial Transplant,2016,31(7):1088-1099.
[14]ABDALLAH E,MOSBAH O,KHALIFA G,et al.Assessment of the relationship between serum soluble klotho and carotid intimamedia thickness and leftven tricular dysfunction in hemodialysis patients[J].Kidney Res Clin Pract,2016,35(1):42-49.
[15]HU MC,KURO-O M,MOE OW.The emerging role of Klotho in clinical nephrology[J].Nephrol Dial Transplant,2012,27(7):2650-2657.
[16]XIE J,YOON J,AN SW,et al.Soluble klotho Protects against Uremic Cardiomyopathy Independently of Fibroblast Growth Factor 23and Phosphate[J].J Am Soc Nephrol,2015,26(5):1150-1160.
[17]CICERI P,VOLPI E,BRENNA I,et al.Combined effects of ascorbic acid and phosphate on rat VSMC osteoblastic differentiation[J].Nephrol Dial Transplant,2012,27(1):122-127.
[18]PROUDFOOT D,SKEPPER J,HEGYI L,et al.Apoptosis regulates human vascular calcification in vitro.Evidence for initiation of vascular calcification by apoptotic bodies[J].Circ Res,2000,87(11):1055-1062.
[19]CICERI P,ELLI F,CAPPELLETTI L,et al.A new in vitro model to delay high phosphate-induced vascular calcification progression[J].Mol Cell Biochem,2015,410(1/2):197-206.
[20]KURO-O M.Klotho,phosphate and FGF-23in ageing and disturbed mineral metabolism[J].Nat Rev Nephrol,2013,9(11):650-660.
[21]SMITH ER,FORD ML,TOMLINSON LA,et al.Phosphorylated fetuin-A-containing calciprotein particles are associated with aortic stiffness and a procalcific milieu in patients with pre-dialysis CKD[J].Nephrol Dial Transplant,2012,27(5):1957-1966.
[22]SMITH ER,FORD ML,TOMLINSON LA,et al.Serumcal cification propensity predicts all-cause mortality in predialysis CKD[J].J Am Soc Nephrol,2014,25(2):339-348.
[23]VIEGAS CS B,SANTOS L,MACEDO AL,et al.Chronic kidney disease circulating calciprotein particles and extracellular vesicles promote vascular calcification:a role for GRP(Gla-Rich Protein)[J].Arterioscler Thromb Vasc Biol,2018,38(3):575-587.
[24]KETTELER M,BLOCK GA,EVENEPOEL P,et al.Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder(CKD-MBD)Guideline Update:what′s changed and why it matters[J].Kidney Int,2017,92:26-36.
[25]SHERMAN RA,AVELLA SR,KAPOIAN T.A dearth of data:the problem of phosphorus in prescription medications[J].Kidney Int,2015,87(6):1097-1099.
[26]NELSON SM,SARABIA SR,CHRISTILAW E,et al.Phosphatecontaining prescription medications contribute to the daily phosphate intake in a third of hemodialysis patients[J].J Ren Nutr,2017,27(2):91-96.
[27]CALDEIRA D,AMARAL T,DAVID C,et al.Educational strategies to reduce serum phosphorus in hyperphosphatemic patients with chronic kidney disease:systematic review with meta-analysis[J].J Ren Nutr,2011,21(4):285-294.
[28]KARAVETIAN M,DE VRIES N,ELZEIN H,et al.Effect of behavioral stage-based nutrition education on management of osteodystrophy among hemodialysis patients,Lebanon[J].Patient Educ Couns,2015,98(9):1116-1122.
[29]Kidney Disease:Improving Global Outcomes(KDIGO)CKD-MBDUpdate Work Group.KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis,Evaluation,Prevention,and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder(CKD-MBD)[J].Kidney Int Suppl,2017,7(1):1-59.
[30]陆任华,倪兆慧,钱家麟,等.醋酸钙治疗血液透析患者高磷血症的有效性与安全性[J].中华肾脏病杂志,2013,29(6):429-434.
[31]DI IORIO B,BELLASI A,RUSSO D.Mortality in kidney disease patients treated with phosphate binders:a randomizedstudy[J].Clin J Am Soc Nephrol,2012,7(8):1370-1371.
[32]GIRAL H,CALDAS Y,SUTHERLAND E,et al.Regulation of rat intestinal Na-dependent phosphate transporters by dietaryphosphate[J].Am J Physiol Renal Physiol,2009,297(5):F1466-1475.
[33]SCHIAVI SC,TANG W,BRACKEN C,et al.Npt2bdeletion attenuates hyperphosphatemia associated with CKD[J].J Am Soc Nephrol,2012,23(10):1691-1700.
[34]LENGLET A,LIABEUF S,EL ESPER N,et al.Efficacy and safety of nicotinamide in haemodialysis patients:the NICORENstudy[J].Nephrol Dial Transplant,2017,32(5):870-879.
[35]EDALAT-NEJAD M,ZAMENI F,TALAIEI A.The effect of niacin on serum phosphorus levels in dialysis patients[J].Indian J Nephrol,2012,22(3):174-178.
[36]LABONTED,CARRERAS CW,LEADBETTER MR,et al.Gastrointestinal inhibition of sodium-hydrogen exchanger 3reduces phosphorus absorption and protects against vascular calcification in CKD[J].J Am Soc Nephrol,2015,26(5):1138-1149.
[37]FERNANDEZ-MARTIN JL,MARTINEZ-CAMBLOR P,DIONISIMP,et al.Improvement of mineral and bone metabolism markers is associated with better survival in haemodialysis patients:the COS-MOS study[J].Nephrol Dial Transplant,2015,30(9):1542-1551.
[2]AGAR BU,AKONUR A,LO YC,et al.Kinetic model of phosphorus mobilization during and after short and conventional hemodialysis[J].Clin J Am Soc Nephrol,2011,6(12):2854-2860.
[3]罗智环,陈俊,闵新文.血管平滑肌细胞在血管中膜钙化中的作用研究进展[J].中国医药报导,2016,13(11):31-34.
[4]石凯峰,张宁,刘世巍,等.高磷血症致慢性肾脏病血管钙化的研究及治疗进展[J].世界中医药,2017,12(2):465-469.
[5]JOVANOVICH A,CHONCHOL M.Chronic kidney disease:reductions in FGF-23levels associated with improved outcomes[J].Nat Rev Nephrol,2015,11(10):572-573.
[6]HU MC,SHI M,ZHANG J,et al.Klotho deficiency causes vascular calcification in chronic kidney disease[J].J Am Soc Nephrol,2011,22(1):124-136.
[7]HUM JM,O′BRYAN LM,TATIPARTHI AK,et al.Chronic hyperphosphatemia and vascular calcification are reduced by stable delivery of soluble klotho[J].J Am Soc Nephrol,2017,28(4):1162-1174.
[8]CHENG L,ZHANG L,YANG J,et al.Activation of peroxisome proliferator-activated receptor gamma inhibits vascular calcification by upregulating Klotho[J].Exp Ther Med,2017,13(2):467-474.
[9]DONATE-CORREA J,MARTN-NUEZ E,MORA-FERNNDEZC,et al.Klotho in cardiovascular disease:Current and future perspectives[J].World J Biol Chem,2015,6(4):352-357.
[10]WANG N,WANG X,SUN B,et al.Role of TGF-β1in production of fibronectin in vascular smooth muscle cells cultured under highphosphate conditions[J].J Nephrol,2013,26(1):213-218.
[11]SEZER S,TUTAL E,BAL Z,et al.Differential influence of vitamin D analogs on left ventricular mass index in maintenance hemodialysis patients[J].Int J Artif Organs,2014,37(2):118-125.
[12]GRABNER A,AMARAL AP,SCHRAM K,et al.Activation of Cardiac Fibroblast Growth Factor Receptor 4Causes Left Ventricular Hypertrophy[J].Cell Metab,2015,22(6):1020-1032.
[13]LEIFHEIT-NESTLER M,GROβE SIEMER R,FLASBART K,et al.Induction of cardiac FGF23/FGFR4expression is associated with left ventricular hypertrophy in patients with chronic kidney disease[J].Nephrol Dial Transplant,2016,31(7):1088-1099.
[14]ABDALLAH E,MOSBAH O,KHALIFA G,et al.Assessment of the relationship between serum soluble klotho and carotid intimamedia thickness and leftven tricular dysfunction in hemodialysis patients[J].Kidney Res Clin Pract,2016,35(1):42-49.
[15]HU MC,KURO-O M,MOE OW.The emerging role of Klotho in clinical nephrology[J].Nephrol Dial Transplant,2012,27(7):2650-2657.
[16]XIE J,YOON J,AN SW,et al.Soluble klotho Protects against Uremic Cardiomyopathy Independently of Fibroblast Growth Factor 23and Phosphate[J].J Am Soc Nephrol,2015,26(5):1150-1160.
[17]CICERI P,VOLPI E,BRENNA I,et al.Combined effects of ascorbic acid and phosphate on rat VSMC osteoblastic differentiation[J].Nephrol Dial Transplant,2012,27(1):122-127.
[18]PROUDFOOT D,SKEPPER J,HEGYI L,et al.Apoptosis regulates human vascular calcification in vitro.Evidence for initiation of vascular calcification by apoptotic bodies[J].Circ Res,2000,87(11):1055-1062.
[19]CICERI P,ELLI F,CAPPELLETTI L,et al.A new in vitro model to delay high phosphate-induced vascular calcification progression[J].Mol Cell Biochem,2015,410(1/2):197-206.
[20]KURO-O M.Klotho,phosphate and FGF-23in ageing and disturbed mineral metabolism[J].Nat Rev Nephrol,2013,9(11):650-660.
[21]SMITH ER,FORD ML,TOMLINSON LA,et al.Phosphorylated fetuin-A-containing calciprotein particles are associated with aortic stiffness and a procalcific milieu in patients with pre-dialysis CKD[J].Nephrol Dial Transplant,2012,27(5):1957-1966.
[22]SMITH ER,FORD ML,TOMLINSON LA,et al.Serumcal cification propensity predicts all-cause mortality in predialysis CKD[J].J Am Soc Nephrol,2014,25(2):339-348.
[23]VIEGAS CS B,SANTOS L,MACEDO AL,et al.Chronic kidney disease circulating calciprotein particles and extracellular vesicles promote vascular calcification:a role for GRP(Gla-Rich Protein)[J].Arterioscler Thromb Vasc Biol,2018,38(3):575-587.
[24]KETTELER M,BLOCK GA,EVENEPOEL P,et al.Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder(CKD-MBD)Guideline Update:what′s changed and why it matters[J].Kidney Int,2017,92:26-36.
[25]SHERMAN RA,AVELLA SR,KAPOIAN T.A dearth of data:the problem of phosphorus in prescription medications[J].Kidney Int,2015,87(6):1097-1099.
[26]NELSON SM,SARABIA SR,CHRISTILAW E,et al.Phosphatecontaining prescription medications contribute to the daily phosphate intake in a third of hemodialysis patients[J].J Ren Nutr,2017,27(2):91-96.
[27]CALDEIRA D,AMARAL T,DAVID C,et al.Educational strategies to reduce serum phosphorus in hyperphosphatemic patients with chronic kidney disease:systematic review with meta-analysis[J].J Ren Nutr,2011,21(4):285-294.
[28]KARAVETIAN M,DE VRIES N,ELZEIN H,et al.Effect of behavioral stage-based nutrition education on management of osteodystrophy among hemodialysis patients,Lebanon[J].Patient Educ Couns,2015,98(9):1116-1122.
[29]Kidney Disease:Improving Global Outcomes(KDIGO)CKD-MBDUpdate Work Group.KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis,Evaluation,Prevention,and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder(CKD-MBD)[J].Kidney Int Suppl,2017,7(1):1-59.
[30]陆任华,倪兆慧,钱家麟,等.醋酸钙治疗血液透析患者高磷血症的有效性与安全性[J].中华肾脏病杂志,2013,29(6):429-434.
[31]DI IORIO B,BELLASI A,RUSSO D.Mortality in kidney disease patients treated with phosphate binders:a randomizedstudy[J].Clin J Am Soc Nephrol,2012,7(8):1370-1371.
[32]GIRAL H,CALDAS Y,SUTHERLAND E,et al.Regulation of rat intestinal Na-dependent phosphate transporters by dietaryphosphate[J].Am J Physiol Renal Physiol,2009,297(5):F1466-1475.
[33]SCHIAVI SC,TANG W,BRACKEN C,et al.Npt2bdeletion attenuates hyperphosphatemia associated with CKD[J].J Am Soc Nephrol,2012,23(10):1691-1700.
[34]LENGLET A,LIABEUF S,EL ESPER N,et al.Efficacy and safety of nicotinamide in haemodialysis patients:the NICORENstudy[J].Nephrol Dial Transplant,2017,32(5):870-879.
[35]EDALAT-NEJAD M,ZAMENI F,TALAIEI A.The effect of niacin on serum phosphorus levels in dialysis patients[J].Indian J Nephrol,2012,22(3):174-178.
[36]LABONTED,CARRERAS CW,LEADBETTER MR,et al.Gastrointestinal inhibition of sodium-hydrogen exchanger 3reduces phosphorus absorption and protects against vascular calcification in CKD[J].J Am Soc Nephrol,2015,26(5):1138-1149.
[37]FERNANDEZ-MARTIN JL,MARTINEZ-CAMBLOR P,DIONISIMP,et al.Improvement of mineral and bone metabolism markers is associated with better survival in haemodialysis patients:the COS-MOS study[J].Nephrol Dial Transplant,2015,30(9):1542-1551.